[Ultraviolet crosslinking in the treatment of keratoconus in patients with thin corneas]

Customised Peripheral Corneal Cross-linking (P-CXL) for Ultra-thin Corneas with Stage III and IV Keratoconus

PURPOSE

This study aims to determine whether customised peripheral corneal cross-linking (P-CXL) can halt keratoconus progression in ultrathin corneas with stage 3 and 4 keratoconus, with thinnest pachymetry well below 400 μm and therefore excluded from most treatment protocols.

METHODS

This retrospective study included 21 eyes with progressive keratoconus and thinnest pachymetry ranging from 97 to 399 μm (mean 315 μm), who underwent P-CXL between 2007 and 2020. The procedure involved preoperative NSAIDs therapy, tomography-guided customized epithelial debridement, the use of both hypo-osmolar and iso-osmolar riboflavin solutions, and 9.0 mW/cm2 UV-A irradiation for 10 minutes. The outcome measures were best spectacle-corrected visual acuity (BSCVA), mean keratometry, maximum keratometry, and thinnest pachymetry.

RESULTS

After a minimum follow-up period of 12 months, P-CXL stabilized or improved mean keratometry and maximum keratometry in 85.7% of eyes (Kavg from 57.48 ± 9.38 to 56.43 ± 8.96 D, p < 0.001; Kmax from 72.77 ± 12.74 to 70.00 ± 11.50 D, p < 0.001), BSCVA in 90.5% of eyes (from 4.48 ± 2.85 to 5.72 ± 3.34 decimals, p < 0.001), and thinnest pachymetry in 81% of eyes (from 315.81 ± 90.05 to 342.33 ± 74.22 μm, p = 0.08). No adverse events and no loss of endothelial cell density occurred.

CONCLUSIONS

Customised peripheral corneal cross-linking (P-CXL) treated very severe keratoconus with a success rate of 85.7% and improved visual acuity and tomographic indicators in most cases. While a longer follow-up and a larger sample would help to support such conclusions to a greater extent, these results allow to broaden the treatment spectrum for patients with stage 3 and 4 keratoconus and contact lens tolerance.

[Changes in precorneal tear film and ocular surface in keratoconic patients after corneal collagen cross-linking]

The article reviews the current available data on the signs and symptoms of dry eye syndrome (DES) in patients with keratoconus (KC), describes the clinical features of DES in KC patients and the morphological features of this type of keratectasia that lead to manifestations of the «dry eye», and highlights the risk factors, consequences of therapeutic measures, concomitant ophthalmological and general somatic diseases that contribute to the development of DES in KC.

[On the tactics for surgical treatment of keratoconus in significantly altered corneal thickness]

PURPOSE

To evaluate the clinical and functional outcomes of bandage therapeutic-optical keratoplasty (BTOK) surgery in patients with keratoconus (KC) and significant changes in corneal thickness.

MATERIAL AND METHODS

Surgical treatment was performed in 15 patients (15 eyes) with stage IV KC aged from 22 to 51 years (mean age - 32.61±7.94 years). The follow-up period lasted 3 years. All patients underwent BTOK surgery using an interlamellar graft with a thickness of 320 to 350 µm.

RESULTS

Uncorrected and best corrected visual acuity increased in all patients after BTOK surgery and did not change statistically significantly during the entire follow-up period (3 years), amounting to 0.47±0.12 and 0.53±0.13, respectively. Keratometric parameters also remained stable by that observation time point and amounted to: K_max - 53.01±2.30 D; K_min - 41.63±2.24 D; K_m - 47.32±1.91 D.

CONCLUSION

The BTOK surgery helps achieve long-term (3 years) visual, optical and strengthening outcomes in stage IV KC patients when the use of other known techniques (corneal collagen crosslinking, corneal segments) is technically impossible because of the risk of complications due to significantly thinned cornea (less than 400 µm).